Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 6/20 | 0.48 |
| ▸ | CA1 known ✓ | P00915 | 6/20 | 0.48 |
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.48 |
| ▸ | THRB known ✓ | P10828 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11605944 | 1.00 | CA12 (0.48) | CA12CA1CA2CA9THRB | |
| SCHEMBL13858780 | 1.00 | CA12 (0.48) | CA12CA1CA2CA9THRB | |
| SCHEMBL20142451 | 1.00 | CA12 (0.48) | CA12CA1CA2CA9THRB | |
| Potassium Ion SCHEMBL9788101 | 0.95 | CA12 (0.47) | CA12CA1CA2CA9THRB | |
| SCHEMBL11043254 | 0.95 | CA12 (0.43) | CA12CA1CA2CA9THRB | |
| SCHEMBL11039650 | 0.95 | CA12 (0.43) | CA12CA1CA2CA9THRB | |
| Potassium Ion SCHEMBL9851169 | 0.95 | CA12 (0.47) | CA12CA1CA2CA9THRB | |
| SCHEMBL10397109 | 0.91 | — | — | |
| Zinc Ion SCHEMBL5450533 | 0.86 | NOS3 (0.44) | CA12CA1CA2CA9POLB | |
| Potassium Ion SCHEMBL11855148 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3581973-B1 | MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME | JOHNSON & JOHNSON VISION CARE (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4502052-A2 | POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME | Johnson & Johnson Vision Care, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-2705390-B9 | MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME | JOHNSON & JOHNSON VISION CARE (US) | 2025-01-22 | — | — | EP | disclosed |
| EP-3296334-B9 | OPHTHALMIC DEVICE AND OPHTHALMIC SOLUTION | JOHNSON & JOHNSON VISION CARE (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-3296334-B1 | OPHTHALMIC DEVICE AND OPHTHALMIC SOLUTION | JOHNSON & JOHNSON VISION CARE (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-2705390-B2 | MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME | JOHNSON & JOHNSON VISION CARE (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11782296-B2 | Polymers and nanogel materials and methods for making and using the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210318469-A1 | MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME | JOHNSON & JOHNSON VISION CARE (US) | 2021-10-14 | — | — | US | disclosed |
| US-11067720-B2 | Medical devices having homogeneous charge density and methods for making same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11029539-B2 | Polymers and nanogel materials and methods for making and using the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2013177506-A2 | POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013176886-A2 | POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013177523-A2 | POLYMERS AND NANOGEL MATERIALS AND METHODS FOR MAKING AND USING THE SAME | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130203813-A1 | MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2566911-A1 | NON-REACTIVE, HYDROPHILIC POLYMERS HAVING TERMINAL SILOXANES AND USES OF THE SAME | Johnson & Johnson Vision Care, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120283353-A1 | MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME | JOHNSON & JOHNSON VISION CARE, INC. | 2012-11-08 | — | — | US | disclosed |
| WO-2012151135-A1 | MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20110275734-A1 | NON-REACTIVE, HYDROPHILIC POLYMERS HAVING TERMINAL SILOXANES AND METHODS FOR MAKING AND USING THE SAME | JOHNSON & JOHNSON VISION CARE, INC. | 2011-11-10 | — | — | US | disclosed |
| WO-2011140318-A1 | NON-REACTIVE, HYDROPHILIC POLYMERS HAVING TERMINAL SILOXANES AND USES OF THE SAME | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-4435304-A | METAL TRITHIOCARBONATJES | PHILLIPS PETROLEUM COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203813-A1 | MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME | LCT, CEL, PIGS | CA12 858/4885CA1 1319/4885CA2 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.